Rituximab Linked to 10-fold Higher IBD Risk in MS Patients
A recent study has found that Rituximab treatment in multiple sclerosis (MS) patients is associated with a tenfold increase in the risk of developing inflammatory bowel disease (IBD). This significant correlation highlights the need for careful monitoring of gastrointestinal symptoms in MS patients receiving Rituximab therapy.
Medscape·




